Across jurisdictions, pharmaceutical companies are navigating recent changes in patent laws. Finnegan attorneys Sanya Sukduang and Emily R. Gabranski spoke with Asia IP on the ever-increasing complexity of patents in the life sciences field and what constitutes patentable subject matter, particularly in the biotechnology sector.
